Skip to content
Strength & muscleResearch article3 min read

In lean adults with type 2 diabetes, higher HbA1c went with a greater chance of low muscle mass

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: The Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus. · Journal of diabetes investigation · 2019 · Original paper ↗

Key takeaway

Among 746 patients with type 2 diabetes, sarcopenia became more frequent as HbA1c rose, especially in lean people: 26.7% at HbA1c of 8.0% or higher, with an odds ratio of 7.82 (P = 0.003) versus HbA1c below 6.5%. Only 52 patients had sarcopenia and the data are cross-sectional, so the direction of the link is unknown.

Study design

Research article

Reading basis

Published abstract

Reading focus

Design & applicability

The research question

High blood sugar is a known risk factor for sarcopenia (loss of muscle mass and function) when people with and without diabetes are compared. It was unclear whether this holds among patients with diabetes, whose blood sugar levels are already relatively high. The authors tested whether glycemic control, measured by HbA1c, is linked to sarcopenia in type 2 diabetes.

Who and how

Cross-sectional analysis of 746 patients with type 2 diabetes (average age 69.9 years) and an older general population sample of 2,067 people (average age 68.2 years). Sarcopenia was defined as weak grip strength or slow usual gait speed together with low skeletal mass index. The authors compared the frequency of sarcopenia across HbA1c categories, adjusting for major covariates such as anthropometric factors and duration of diabetes.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Of the patients with type 2 diabetes, 52 had sarcopenia. Its frequency rose in a linear way with HbA1c, particularly in lean patients: 20.3% at HbA1c of 7.0% to under 8.0% and 26.7% at 8.0% or higher (the abstract's figure for the lowest groups is garbled, with 18.5% listed for one of them).
  2. 2
    The link held after adjustment, compared with HbA1c below 6.5%: odds ratio 4.38 at 6.5% to under 7.0% (P = 0.030), 4.29 at 7.0% to under 8.0% (P = 0.024), and 7.82 at 8.0% or higher (P = 0.003).
  3. 3
    HbA1c of 8.0% or higher was tied to low skeletal mass index (OR 5.42, P < 0.001) rather than weak grip strength (OR 1.89, P = 0.058) or slow gait speed (OR 1.13, P = 0.672).
  4. 4
    No significant association was seen in the general population, which had better glycemic profiles.

Limits & uncertainty

  1. 1
    A cross-sectional design cannot show whether high blood sugar leads to muscle loss or whether muscle loss worsens blood sugar control.
  2. 2
    Only 52 of 746 patients had sarcopenia, so the category estimates are based on few cases, and the odds ratios have unreported uncertainty in the abstract.
  3. 3
    Results were strongest in lean patients, a subgroup finding, and may not apply to people with obesity.
  4. 4
    This reading is based on the abstract only.

What to take from it

The finding suggests that muscle mass deserves attention in people with diabetes and poorly controlled blood sugar, even if they are not overweight. It does not show that lowering HbA1c will restore muscle. Decisions about diabetes treatment, diet and exercise belong with your clinician.

Reading your own data

If you wear a continuous glucose monitor or log HbA1c results, look at the trend over months. Body weight can hide muscle loss, so pair it with a repeatable strength or grip measure and, where available, a body composition scan. Use the same device and conditions each time.

How to read this evidence

The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Aims/introduction

Hyperglycemia is a risk factor for sarcopenia when comparing individuals with and without diabetes. However, no studies have investigated whether the findings could be extrapolated to patients with diabetes with relatively higher glycemic levels. Here, we aimed to clarify whether glycemic control was associated with sarcopenia in patients with type 2 diabetes.

Materials and methods

Study participants consisted of patients with type 2 diabetes (n = 746, the average age was 69.9 years) and an older general population (n = 2,067, the average age was 68.2 years). Sarcopenia was defined as weak grip strength or slow usual gait speed and low skeletal mass index.

Results

Among patients with type 2 diabetes, 52 were diagnosed as having sarcopenia. The frequency of sarcopenia increased linearly with glycated hemoglobin (HbA1c) level, particularly in lean individuals (HbA1c <6.5%, 7.0%, ≥6.5% and <7.0%: 18.5%; HbA1c ≥7.0% and <8.0%: 20.3%; HbA1c ≥8.0%: 26.7%). The linear association was independent of major covariates, including anthropometric factors and duration of diabetes (HbA1c <6.5%: reference; ≥6.5% and <7.0%: odds ratio [OR] 4.38, P = 0.030; HbA1c ≥7.0% and <8.0%: 4.29, P = 0.024; HbA1c ≥8.0%: 7.82, P = 0.003). HbA1c level was specifically associated with low skeletal mass index (HbA1c ≥8.0%: OR 5.42, P < 0.001) rather than weak grip strength (OR 1.89, P = 0.058) or slow gait speed (OR 1.13, P = 0.672). No significant association was observed in the general population with a better glycemic profile.

Conclusions

Poor glycemic control in patients with diabetes was associated with low muscle mass.

Sources & attribution

Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: The Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus.

Sugimoto K, Tabara Y, Ikegami H, Takata Y, Kamide K, Ikezoe T, Kiyoshige E, Makutani Y, Onuma H, Gondo Y, Ikebe K, Ichihashi N, Tsuboyama T, Matsuda F, Kohara K, Kabayama M, Fukuda M, Katsuya T, Osawa H, Hiromine Y, Rakugi H.

Journal of diabetes investigation · 2019-06-01

DOI: 10.1111/jdi.13070 ↗PubMed · 31074209 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Overview of reviews

ACSM review of 137 reviews: resistance training works, and few programme details matter

The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.

Medicine & Science in Sports & Exercise

In-depth explainersRead study →
·Trial meta-analysis

Nearly every resistance training plan beat no exercise; heavy loads led for strength

In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.

British Journal of Sports Medicine

In-depth explainersRead study →
·Observational meta-analysis

Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes

Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.

British Journal of Sports Medicine

In-depth explainersRead study →
·Trial meta-analysis

Protein supplements and weight training: small extra gains, smaller in older adults

Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.

British Journal of Sports Medicine

In-depth explainersRead study →
Strength & muscle →